Skip to main content
Premium Trial:

Request an Annual Quote

Broad to be Early Access Partner for RainDance Sequencing Application

NEW YORK (GenomeWeb News) – RainDance Technologies today said that the Broad Institute will become an early access partner for the firm’s RDT 1000 instrument and Sequence Enrichment Solution.
The Broad will have access to the RDT 1000 microfluidics-based instrument, consumables kits, and expert training for sequence enrichment, said RainDance. In addition to its genomic research initiatives, the Broad will investigate using the RDT 1000 for its experiments related to the human microbiome.
The RDT 1000 generates picoliter-volume PCR reactions at a rate of 10 million reactions per hour, and the Sequence Enrichment application uses a library of PCR primers in droplets to amplify hundreds to thousands of genomic loci in a single tube, the company said.
“The program provides an opportunity for some of the world’s leading scientists in genomic research to become experienced with our technology months prior to its commercial launch,” said Chris McNary, president and CEO of RainDance, in a statement.
RainDance previously said that it intends to commercially launch the system during the first quarter of 2009.
The Broad is the third early access partner announced by RainDance, following the Genome Center at the Washington University School of Medicine in St. Louis last month and the J. Craig Venter Institute in October.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.